医学临床研究
  2025年4月5日 星期六           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2022, Vol. 39 Issue (9): 1368-1371    DOI: 10.3969/j.issn.1671-7171.2022.09.024
  论著 本期目录 | 过刊浏览 | 高级检索 |
文拉法辛联合纳美芬治疗酒精性精神和行为障碍的临床效果
徐娟1, 李小雪2
1.安康市疾病预防控制中心,陕西 安康 725000;
2.安康市中心医院,陕西 安康 725000
Analysis of Clinical Effect of Venlafaxine Combined with Namefene in the Treatment of Alcoholic Mental and Behavioral Disorders
XU Juan, LI Xiao-xue
Ankang Center for Disease Control and Preverntion,Ankang Shaanxi 725000
全文: PDF (1138 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨文拉法辛联合纳美芬治疗酒精性精神和行为障碍的临床效果。【方法】选取2019年5月至2020年3月安康市中心医院收治的72例酒精性精神和行为障碍患者,采用随机数字法将其分为观察组和对照组,每组36例。对照组予以常规治疗及纳美芬治疗,观察组在对照组基础上予以文拉法辛治疗。比较两组治疗效果、不良反应发生率,治疗前后PANSS评分、神经细胞因子[脑源神经营养因子(BDNF)、神经生长因子(NGF)、神经营养素-3(NT-3)]水平及蒙特利尔认知评估量表(MoCA)评分、洛文斯顿作业疗法认知评定量表(LOTCA)。【结果】治疗28 d后,观察组总有效率为94.44%(34/36),高于对照组的77.78%(28/36),差异有统计学意义(χ2=4.18,P=0.04);两组患者阳性症状评分、阴性症状评分、一般精神病理评分及总分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组患者血清BDNF、NGF、NT-3水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组患者LOTCA评分、MoCA评分高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。两组患者恶心、呕吐、头晕、嗜睡、口干、腹泻、皮肤瘙痒发生率比较,差异无统计学意义(P>0.05)。【结论】文拉法辛联合纳美芬治疗有助于调节酒精性精神和行为障碍患者神经细胞因子水平,提高临床治疗效果,改善患者精神症状,减轻认知功能障碍,且安全性较好。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
徐娟
李小雪
关键词 酒精性神经病盐酸文拉法辛/治疗应用麻醉品拮抗药/治疗应用    
Abstract:【Objective】To investigate the clinical effect of venlafaxine combined with Namefene in the treatment of alcoholic mental and behavioral disorders.【Methods】A total of 72 patients with alcoholic mental and behavioral disorders admitted to Ankang Central Hospital from May 2019 to March 2020 were randomly divided into observation group and control group with 36 patients in each group. The control group was treated with routine therapy and Namefene, while the observation group was treated with venlafaxine on the basis of the control group. The therapeutic effect, adverse reaction rate, PANSS score, levels of neurocytokines [brain derived neurotrophic factor(BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3)], and the scores of Loewenstein Occupational Therapy Cognitive Assessment Scale (LOTCA) and Montreal Cognitive Assessment Scale (MoCA) before and after treatment were compared between the two groups. 【Results】 After 28 days of treatment, the total effective rate in the observation group was 94.44% (34/36), higher than that in the control group [77.78% (28/36)], with a statistically significant difference(χ2=4.18,P=0.04);The positive symptom score, negative symptom score, general psychopathology score and total score of the two groups were lower than those before treatment, and the observation group was lower than the control group, with a statistically significant difference (P<0.05); The levels of serum BDNF, NGF and NT-3 in the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group, with a statistically significant difference (P<0.05); The scores of LOTCA and MoCA in the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group, with a statistically significant difference (P<0.05). There was no significant difference between the two groups in the incidence of nausea, vomiting, dizziness, lethargy, dry mouth, diarrhea and skin itching (P>0.05). 【Conclusion】 Venlafaxine combined with Namefene is helpful to regulate the level of neurocytokines in patients with alcoholic mental and behavioral disorders, improve clinical treatment effect, improve mental symptoms, reduce cognitive dysfunction, and has good safety.
Key wordsAlcoholic Neuropathy    Venlafaxine Hydrochloride/TU    Narcotic Antagonists/TU
收稿日期: 2021-08-20     
中图分类号:  R749.3  
引用本文:   
徐娟, 李小雪. 文拉法辛联合纳美芬治疗酒精性精神和行为障碍的临床效果[J]. 医学临床研究, 2022, 39(9): 1368-1371.
XU Juan, LI Xiao-xue. Analysis of Clinical Effect of Venlafaxine Combined with Namefene in the Treatment of Alcoholic Mental and Behavioral Disorders. JOURNAL OF CLINICAL RESEARCH, 2022, 39(9): 1368-1371.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.09.024     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I9/1368
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn